1 / 8

Treatment 6 cycles of: Doxorubicin 60 mg/m 2 IV* Day 1 in 21-day cycles Sorafenib 400 mg po bid

Final Results From a Phase II, Randomized, Double-blind Study of Sorafenib Plus Doxorubicin Versus Placebo Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma. Authors: Abou-Alfa GK, Johnson P, Knox J, Davidenko I, Lacava J, Leung T, Mori A, Leberre M-A, Voliotis D, & Saltz LB

tab
Download Presentation

Treatment 6 cycles of: Doxorubicin 60 mg/m 2 IV* Day 1 in 21-day cycles Sorafenib 400 mg po bid

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Final Results From a Phase II, Randomized, Double-blind Study of Sorafenib Plus Doxorubicin Versus Placebo Plus Doxorubicin in Patients With Advanced HepatocellularCarcinoma Authors: Abou-Alfa GK, Johnson P, Knox J, Davidenko I, Lacava J, Leung T, Mori A, Leberre M-A, Voliotis D, & Saltz LB Date posted: October 22, 2007

  2. Randomized Phase II Study N= 96 Primary Outcome: TTP • Treatment 6 cycles of: • Doxorubicin 60 mg/m2 IV* Day 1 in 21-day cycles • Sorafenib 400 mg po bid ThenSorafenib 400 mg po bid R * In approved circumstances , doxorubicin doses of up to 450 mg/m2 allowed • Treatment 6 cycles of: • Doxorubicin 60 mg/m2 IV* Day 1 in 21-day cycles • Placebo 2 tablets po bid ThenPlacebo 2 tablets po bid • Advanced • Hepatocellular CA • ECOG 0-2 • Child’s Pugh A • No Previous • Chemoembolization

  3. RESULTS - Demographics

  4. RESULTS • Considering the interim results of the Phase III SHARP trial(sorafenib vs placebo), an Independent Data Monitoring Committee (DMC) performed an interim analysis in January 2007 • “DMC would advise the sponsor to consider discontinuation of this Phase II trial”

  5. RESULTS

  6. TOXICITY

  7. STUDY COMMENTARY • This randomized phase II trial demonstrated a statistically and clinically significant survival benefit for adriamycin and sorafenib vs adriamycin and placebo • Coupled with the SHARP trial (Sorafenib vs Placebo - Llovet, ASCO 2007) supports growing body of evidence for sorafenib in HCC • Larger trials necessary to determine optimal role of adriamycin/sorafenib in HCC

  8. BOTTOM LINE FOR CANADIAN MEDICAL ONCOLOGISTS • Sorafenib and adriamycin and sorafenib as a single agent could be considered for use in patients with HCC who are candidates for systemic therapy • Cost and reimbursement of sorafenib may limit its widespread use in Canada

More Related